Sign in

ANTH on NASDAQ

Anthera Pharmaceuticals

Logo: Non-free logo, via Wikipedia6

American biopharmaceutical company

Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.3 Wikipedia text CC BY-SA 4.0

$0.00 up 0.00 (0.00%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

2004Founded1

Compare with another stock.

  • TickerANTH on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersHayward1
  • Websitewww.anthera.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address25801 Industrial Boulevard, Suite B, Hayward, Ca 945457
  • Filer categorySmaller reporting company7
  • LEI549300Z72RGRIU8IX3114
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 38507894

See how the biggest companies compare on our leaderboards

Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.3

What it owns

What Anthera Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.3M9 Dec 31, 2017$2.5M9 Dec 31, 2016−5.5%
Accumulated depreciation$1.9M9 Dec 31, 2017$1.7M9 Dec 31, 2016+8.5%
Property and equipment, net$482.0K9 Dec 31, 2017$763.0K9 Dec 31, 2016−36.8%

Real estate and locations

ItemLatestA year beforeChange
Area of real estate14,000 sq ft9 Dec 31, 201714,000 sq ft10 Dec 31, 20150%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.2M9 Dec 31, 2017$20.8M9 Dec 31, 2016−89.5%

Leadership

Who has led Anthera Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Paul F. Truex2010–2016

Chair

  1. Paul F. Truex2016

President

  1. Paul F. Truex2010–2015

Chief financial officer

  1. Christopher P. Lowe2010–2013
20052010201520202025
Board members and other officers (30)

Products and brands

Blisibimod

Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. It is primarily expressed by macrophages, monocytes and dendritic cells. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. Blisibimod is currently being evaluated in IgA nephropathy.

Sollpura

In July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.

From Wikipedia’s article on Anthera Pharmaceuticals, shared under CC BY-SA 4.0.8

Timeline

  1. Feb 23, 2010New chief executive Paul F. Truex becomes CEO11
  2. 2004Founded Founded1

SEC filer profile

How Anthera Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAnthera Pharmaceuticals Inc2
  • CIK0001316175
  • Employer ID (EIN)20-18520162
  • Filer statusSmaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address25801 Industrial Boulevard, Suite B, Hayward, CA 945452
  • Phone(510) 856-56002
  • Shares outstanding26,179,302 as of Apr 30, 201842
  • Public float$17.1M as of Jun 30, 20179
  • On EDGAR sinceJan 31, 20052
  • Filings690 in all: 4 (235), 8-K (127), SC 13G/A (42), 3 (34), 10-Q (25), SC 13G (24), 424B5 (23), EFFECT (20)2
    All 44 form types

    SC 13D/A (14), POS AM (13), DEF 14A (10), S-8 POS (9), UPLOAD (9), 10-K (8), CORRESP (8), S-8 (8), 4/A (7), DEFA14A (7), S-3 (7), S-1/A (6), 424B3 (5), 5 (5), REGDEX (5), SC 13D (5), PRE 14A (4), 3/A (3), ARS (3), CT ORDER (3), S-1 (3), 10-Q/A (2), AW (2), REGDEX/A (2), 10-K/A (1), 15-12B (1), 25 (1), 424B1 (1), 424B4 (1), 8-A12B (1), AW WD (1), CERTNAS (1), D (1), D/A (1), RW (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2018
    Quarterly report (10-Q) May 15, 2018
    Proxy statement (DEF 14A) Dec 4, 2017
    Latest 8-K (8-K) Jul 9, 2018

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceANTH quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42